GEOGRAPHIC ATROPHY (GA)
Clinical trials for GEOGRAPHIC ATROPHY (GA) explained in plain language.
Never miss a new study
Get alerted when new GEOGRAPHIC ATROPHY (GA) trials appear
Sign up with your email to follow new studies for GEOGRAPHIC ATROPHY (GA), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to halt blind spots in dry AMD
Disease control Recruiting nowThis study tests two experimental drugs, pozelimab and cemdisiran, alone or together, to see if they can slow the growth of blind spots (geographic atrophy) in people with advanced dry age-related macular degeneration. About 975 adults with moderate vision loss will receive injec…
Matched conditions: GEOGRAPHIC ATROPHY (GA)
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 06:41 UTC
-
New eye drug aims to halt blinding disease in thousands
Disease control Recruiting nowThis study tests an experimental drug called ONL1204, given as an eye injection, to see if it can slow the growth of blind spots (geographic atrophy) in people with dry age-related macular degeneration. About 324 adults aged 55 and older will receive either the drug or a sham inj…
Matched conditions: GEOGRAPHIC ATROPHY (GA)
Phase: PHASE2 • Sponsor: ONL Therapeutics • Aim: Disease control
Last updated May 26, 2026 04:38 UTC
-
Experimental eye injection aims to slow vision loss from geographic atrophy
Disease control Recruiting nowThis early-stage study tests an experimental drug called pozelimab, given as an injection into the eye, for people with geographic atrophy (GA), a condition that damages the retina and causes vision loss. The main goal is to check the drug's safety and tolerability in 54 particip…
Matched conditions: GEOGRAPHIC ATROPHY (GA)
Phase: PHASE1 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 04:37 UTC